Results 61 to 70 of about 25,098 (228)

Dialysis and Pregnancy: Optimizing Therapy for Best Maternal and Fetal Outcomes

open access: yesHemodialysis International, EarlyView.
ABSTRACT Pregnancy in women with end‐stage kidney disease (ESKD) requiring dialysis remains high risk, with significant maternal and fetal complications. While fertility rates are markedly reduced in this population, advances in dialysis care and obstetric management have led to increasing reports of successful pregnancies.
Shreepriya Mangalgi, Silvi Shah
wiley   +1 more source

Gendered Experiences of Intravenous Iron Infusion Reactions: A Patient Perspective

open access: yesJournal of Patient Experience
Hypophosphatemia following iron infusion is thought to be a relatively rare complication of intravenous iron infusion, though research is beginning to demonstrate that it occurs more often than previously assumed.
Roxanna Nasseri Pebdani PhD, CRC, SFHEA
doaj   +1 more source

Hypophosphatemia as Unusual Cause of ARDS in Cushing’s Syndrome Secondary to Ectopic CRH Production. A Case Report

open access: yesThe Scientific World Journal, 2008
Hypophosphatemia is an unusual cause of acute respiratory distress syndrome (ARDS). We describe a hypophosphatemia-related ARDS case report of a 50-year-old woman with ACTH dependent Cushing's syndrome secondary to ectopic CRH production.
Stefania Mondello   +6 more
doaj   +1 more source

Association between phosphate disturbances and mortality among critically ill patients with sepsis or septic shock

open access: yesBMC Pharmacology and Toxicology, 2021
Objective The aim of this study is to examine the association of hypophosphatemia and hyperphosphatemia on the first day of ICU admission with mortality in septic critically ill patients. Methods In this retrospective cohort study, all adult patients who
Shmeylan A. Al Harbi   +6 more
doaj   +1 more source

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies. [PDF]

open access: yes, 2014
Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced cancer patients.
Bakris, GL   +13 more
core   +2 more sources

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

Gingival and Periodontal Diseases and Conditions in Children and Adolescents: Consensus Report

open access: yesJournal of Clinical Periodontology, EarlyView.
ABSTRACT Background The objectives of this Focused Workshop were to update the epidemiology, aetiology, risk factors, diagnosis and management of gingival and periodontal diseases and conditions in children and adolescents, and to explore the applicability of the 2018 Classification in children and adolescents.
Iain Chapple   +30 more
wiley   +1 more source

Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity

open access: yesJournal of International Medical Research, 2022
Objective Monthly scanning with triple-dose gadopentetate dimeglumine has been shown to be associated with progressive increases in bone T1 hyperintensity, hypophosphatemia, and leukopenia.
Daniel Chen   +7 more
doaj   +1 more source

Hypophosphatemia in the first seizure clinic: Data from a second UK center

open access: yes
Epilepsia Open, EarlyView.
Thomas Atkinson   +2 more
wiley   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy